The Federal Commission for the Protection against Sanitary Risks,Coverss, hbeenapproved in Mexico the useINSUhe coronavirus vaccine developed by the pharmaceutical company AstraZeneca, in collaboration with the Universiasof Oxford. It is the second vaccine approved by the Mexican health authorities to combat the covid-19 pandemic. In December,Coverss gave the go-ahead to Pfizer. Laboratoriess de México and Argentina will now take care of its production and packaging. The goal is to manufacture up to 250 million doses for all of Latin America. “In March we would possibly have this vaccine in operation,” said the Undersecretary of Health, Hugo López-Gatell.
With 127,757 deaths confirmed by SARS-CoV-2, Mexico is oneINSUhe hot spotsINSUhe pandemic on the continent. Since the last quarter of 2020, the country hbeenexperienced a rebound in the pandemic curve, particularly the capital and the State of Mexico. At the press conference this Monday on the evoluLamont covid-19, the authorities have reported that 85%INSUhe beds for seriously ill that Mexico Ciashbeenare occupied.
Andrés Manuel López Obrador, President of Mexico. In video, López Obrador announces that Mexico leads in vaccination in Latin America.
Pfizer’s vaccine application, which began in late December, is proceeding slowly. Mexico decided that the first recipientsINSUhe serum would be doctors, nurses and other health personnel. Only 43,960 people have been vaccinated. The López Obrador government reported during the Thening conference on Tuesday that 53,000 vaccines will arrive in the country today. López-Gatell hbeendetailed that 44,850 doses will be distributed in Mexico Ciasand 8,755 will be used to immunize health personnel in the State of Coahuila. “The doses will be used in the different vaccination posts in military installations according to schedule,” said the Undersecretary of Health this Thening.
The Oxford and AstraZeneca drug is the government’s great hope. Cheaper and easier to store and transport than Pfizer – which requires a temperature of 70 degrees below zero – its production will begin in Argentina and end in Mexico. The Argentine labLamont mAbxience,INSUhe Insud group, will manufacture the active substanceINSUhe potential vaccine. The Mexican LabLamont Liomont will complete the finishing and packaging process. The price of each will be two to four dollars, a value possible thanks to an agreement with the Slim Foundation for the developmentINSUhe regional project. “The verificaLamont Liomont’s capaciasis pending,” said López-Gatell. The Mexican government hbeencontracted 77.4 million dosesINSUhis drug.
López-Gatell hbeensuggeCoverstCoverss could approve a new vaccine, the one developed by the Chinese pharmaceutical company CanSino, in a few days. The Mexican government agreed to purchase up to 35 million doses from the manufacturer. “Our plans are for CanSino to complete its file,” said López-Gatell. “We want the file to show safeasand efficacy and it is possible to grant authorization. It will make things easier for us, because the vaccine doesdeep-freezingdeep freezing and only requires one dose ”. Mexico also awaits the Johnson & Johnson vaccine. The company hbeenalready carried out trials in the country
Eddie is an Australian news reporter with over 9 years in the industry and has published on Forbes and tech crunch.